{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"83.6","value":"201"},{"groupId":"OG001","spread":"94.7","value":"266"},{"groupId":"OG002","spread":"93.2","value":"343"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"99"},{"groupId":"OG002","value":"7"}],"units":"Participants"}],"title":"C1D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"93.2","value":"210"},{"groupId":"OG001","spread":"113","value":"293"},{"groupId":"OG002","spread":"165","value":"340"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"89"},{"groupId":"OG002","value":"7"}],"units":"Participants"}],"title":"C1D8"}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"99"},{"groupId":"OG002","value":"7"}],"units":"Participants"}],"description":"Maximum Observed Plasma Concentration INCB057643 administered as monotherapy in fasted state.","dispersionType":"Standard Deviation","groups":[{"description":"Initial cohort dose of INCB057643 monotherapy at the protocol specified starting dose in the Part 1 TGA,TGB,TGC, and Part 2 TGA","id":"OG000","title":"8mg QD INCB057643"},{"description":"Initial cohort dose of INCB057643 monotherapy at the protocol specified starting dose in the Part 1 TGA,TGB, and Part 2 TGA,TGB.","id":"OG001","title":"12mg QD INCB057643"},{"description":"Initial cohort dose of INCB057643 monotherapy at the protocol specified starting dose in the Part 1 TGA","id":"OG002","title":"16mg QD INCB057643"}],"paramType":"MEAN","populationDescription":"PK evaluable population includes all subjects who received at least 1 dose of study drug and had at least 1 PK sample collected and analyzed","reportingStatus":"POSTED","timeFrame":"Predose, 0.5, 1, 2, 4, 6, 8 hours on C1D1 and C1D8","title":"Cmax: Maximum Observed Plasma Concentration of INCB057643.","type":"SECONDARY","unitOfMeasure":"nM"}